Literature DB >> 8717160

The contribution by monoamine oxidase and catechol-O-methyltransferase to the total-body and pulmonary plasma clearance of catecholamines.

B Friedgen1, R Wölfel, K H Graefe.   

Abstract

To study the effects of inhibition of catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO) on the removal of circulating catecholamines, anaesthetized rabbits were infused for 120 min with 3H-labelled noradrenaline, adrenaline and dopamine. Total-body plasma clearances (Cltot) and pulmonary fractional extractions (ERp) of the infused amines and the cardiac output of plasma (CO(p)) were determined under steady-state conditions at the end of each of two consecutive 60-min treatment periods. MAO and COMT were inhibited by treatment with pargyline (40 mg/kg) and tolcapone (3 mg/kg followed by 1.5 mg/kg given every 30 min), respectively. Two groups of animals were studied. Group I involved animals treated with tolcapone throughout and given pargyline at the beginning of the second treatment period. In group II, pargyline was given at the beginning of the first, and the treatment with tolcapone was started at the beginning of the second treatment period. As previous experiments had shown that COMT inhibition alone is without any effect on Cltot of the three catecholamines considered here, the results obtained in the first treatment period of group I can be taken to reflect control results. At the end of the first treatment period, Cltot of noradrenaline, adrenaline and dopamine (expressed as a percentage of CO(p)) was 88%, 85% and 142%, respectively, in group I (COMT inhibition) and 67%, 77% and 115%, respectively, in group II (MAO inhibition; P < 0.05 for the group difference regarding Cltot of noradrenaline and dopamine). MAO inhibition on top of COMT inhibition (group I) lowered Cltot of noradrenaline, adrenaline and dopamine by 23%, 12% and 26%, respectively, and COMT inhibition on top of MAO inhibition (group II) reduced Cltot of these catecholamines by 13%, 20% and 17%, respectively. At the end of the first treatment period, the pulmonary plasma clearance (Clp = ERp x CO(p)) of noradrenaline and dopamine was 13 and 25 ml kg-1 min-1, respectively, in group I and 12 and 28 ml kg-1 min-1, respectively, in group II. Clp of adrenaline did not differ from zero in either group. Clp of noradrenaline and dopamine was reduced by 74% and 70%, respectively, when both enzymes were inhibited in group I and by 70% and 67%, respectively, when both enzymes were inhibited in group II. Hence, inhibition of either MAO or COMT alone had little, if any, effect on the removal of noradrenaline, adrenaline and dopamine on passage through the systemic and pulmonary circulation. Combined inhibition of both MAO and COMT was highly effective in reducing the pulmonary clearance of noradrenaline and dopamine, but produced only minor decreases in the total-body clearance of all three catecholamines.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8717160     DOI: 10.1007/BF00168757

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  30 in total

1.  Ro 40-7592, a novel, very potent, and orally active inhibitor of catechol-O-methyltransferase: a pharmacological study in rats.

Authors:  G Zürcher; H H Keller; R Kettler; J Borgulya; E P Bonetti; R Eigenmann; M Da Prada
Journal:  Adv Neurol       Date:  1990

Review 2.  Catecholamine metabolism: basic aspects and clinical significance.

Authors:  I J Kopin
Journal:  Pharmacol Rev       Date:  1985-12       Impact factor: 25.468

3.  Technique for measurement of norepinephrine and 5-hydroxytryptamine uptake by rabbit lung.

Authors:  C N Gillis; Y Iwasawa
Journal:  J Appl Physiol       Date:  1972-09       Impact factor: 3.531

4.  Inhibition by pargyline of cardiovascular amine oxidase activity.

Authors:  J A Fuentes; N H Neff
Journal:  Biochem Pharmacol       Date:  1977-11-15       Impact factor: 5.858

Review 5.  Assessment of sympathetic nervous function in humans from noradrenaline plasma kinetics.

Authors:  M Esler
Journal:  Clin Sci (Lond)       Date:  1982-03       Impact factor: 6.124

Review 6.  The interaction of transport mechanisms and intracellular enzymes in metabolizing systems.

Authors:  U Trendelenburg
Journal:  J Neural Transm Suppl       Date:  1990

7.  The effect of partial inhibition of monoamine oxidase on the steady-state rate of deamination of 3H-catecholamines in two metabolizing systems.

Authors:  L Cassis; J Ludwig; M Grohmann; U Trendelenburg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-07       Impact factor: 3.000

8.  Vascular uptake of catecholamines in perfused lungs of the rat occurs by the same process as Uptake1 in noradrenergic neurones.

Authors:  L J Bryan-Lluka; N N Westwood; S R O'Donnell
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-03       Impact factor: 3.000

9.  The noradrenaline rate in the anaesthetized rabbit: facilitation by adrenaline.

Authors:  H Majewski; L Hedler; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-10       Impact factor: 3.000

10.  Chronic clorgyline treatment enhances release of norepinephrine following sympathetic stimulation in the rat.

Authors:  J P Finberg; I J Kopin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-03       Impact factor: 3.000

View more
  3 in total

1.  The role of extraneuronal amine transport systems for the removal of extracellular catecholamines in the rabbit.

Authors:  B Friedgen; R Wölfel; H Russ; E Schömig; K H Graefe
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996 Aug-Sep       Impact factor: 3.000

Review 2.  Sympathetic nerve function--assessment by radioisotope dilution analysis.

Authors:  Graeme Eisenhofer
Journal:  Clin Auton Res       Date:  2005-08       Impact factor: 4.435

Review 3.  Adverse drug reactions in patients with phaeochromocytoma: incidence, prevention and management.

Authors:  Graeme Eisenhofer; Graham Rivers; Alejandro L Rosas; Zena Quezado; William M Manger; Karel Pacak
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.